title: Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure.
abstract: Patients with multiple myeloma and dialysis-dependent renal failure have dismal outcomes. In this retrospective analysis of a case series, we evaluated 27 consecutive patients, all of whom required haemodialysis at the time of first-line induction therapy with either bortezomib or a standard regimen followed by high-dose chemotherapy and auto-SCT. The overall response rate was significantly better after bortezomib-based induction before auto-SCT (83% vs 36%, P=0.02) and at day +100 post auto-SCT (100% vs 58%, P=0.01). Bortezomib also prolonged EFS and furthermore, a trend towards a shorter time on haemodialysis was observed in the bortezomib group at a median of 6.1 months (0.2-68.2 months) vs 17.1 months (0.7-94.3 months, P=0.38) in patients who had received vincristine, adriamycin, dexamethasone or vincristine, adriamycin, dexamethasone-like induction regimens. These data demonstrate the superior efficacy of bortezomib-based induction therapy in transplant-eligible patients with end-stage renal failure.
authors.affiliation: 1] Max-Eder-Group 'Experimental Therapies for Hematologic Malignancies', Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany [2] Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany.
authors.forename: I
authors.initials: I
authors.lastname: Breitkreutz
authors.affiliation: Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Heiss
authors.affiliation: Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Perne
authors.affiliation: Division of Nephrology, Heidelberg University Hospital, Heidelberg, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Beimler
authors.affiliation: Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany.
authors.forename: D
authors.initials: D
authors.lastname: Jäger
authors.affiliation: Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
authors.forename: G
authors.initials: G
authors.lastname: Egerer
authors.affiliation: Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
authors.forename: A D
authors.initials: AD
authors.lastname: Ho
authors.affiliation: Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Neben
authors.affiliation: Division of Nephrology, Heidelberg University Hospital, Heidelberg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Zeier
authors.affiliation: 1] Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany [2] Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Goldschmidt
authors.affiliation: 1] Max-Eder-Group 'Experimental Therapies for Hematologic Malignancies', Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany [2] Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
authors.forename: M S
authors.initials: MS
authors.lastname: Raab
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D064592:Autografts; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D018572:Disease-Free Survival; D006801:Humans; D007676:Kidney Failure, Chronic / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000628:therapy; D011719:Pyrazines / Q000008:administration & dosage*; D006435:Renal Dialysis; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D019172:Transplantation Conditioning
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib
references.citation: Am J Hematol. 2012 Jun;87(6):640
references.pmid: 22473521
references.citation: Eur J Haematol. 2010 Mar;84(3):223-8
references.pmid: 19930441
references.citation: Leukemia. 2013 Feb;27(2):423-9
references.pmid: 22763386
references.citation: Arch Intern Med. 1998 Sep 28;158(17):1889-93
references.pmid: 9759684
references.citation: Clin J Am Soc Nephrol. 2009 Apr;4(4):745-54
references.pmid: 19339414
references.citation: Eur J Haematol. 2005 Jul;75(1):27-33
references.pmid: 15946307
references.citation: Blood. 2007 Mar 15;109(6):2604-6
references.pmid: 17138816
references.citation: Haematologica. 2006 Nov;91(11):1555-8
references.pmid: 17082013
references.citation: Leukemia. 2006 Sep;20(9):1467-73
references.pmid: 16855634
references.citation: Eur J Haematol. 2000 Sep;65(3):175-81
references.pmid: 11007053
references.citation: Nephrol Dial Transplant. 2010 Feb;25(2):419-26
references.pmid: 19767634
references.citation: Nephrol Dial Transplant. 2010 Apr;25(4):1200-6
references.pmid: 20037169
references.citation: Mayo Clin Proc. 2003 Jan;78(1):21-33
references.pmid: 12528874
references.citation: Biol Blood Marrow Transplant. 2009 Jul;15(7):812-6
references.pmid: 19539212
references.citation: J Clin Oncol. 2005 Dec 20;23(36):9219-26
references.pmid: 16275935
references.citation: Bone Marrow Transplant. 2013 Nov;48(12):1543-7
references.pmid: 23912663
references.citation: Br J Haematol. 1995 Dec;91(4):854-9
references.pmid: 8547129
references.citation: Haematologica. 2007 Oct;92(10):1411-4
references.pmid: 17768111
references.citation: Br J Haematol. 2001 Sep;114(4):822-9
references.pmid: 11564069
references.citation: Kidney Int. 2008 Jun;73(11):1282-8
references.pmid: 18385667
references.citation: Eur J Haematol. 2010 Jul;85(1):1-5
references.pmid: 20192988